The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Genomic differences between smoldering and multiple myeloma
Eileen Boyle, MD, PhD, University College London, London, UK, discusses the genomic differences between smoldering multiple myeloma (SMM) and multiple myeloma (MM). SMM exhibits fewer high-risk translocations like t(4;14), while MM has more adverse mutations such as del(17p), gain(1q), and del(13q). Additionally, mutations in NRAS and KRAS are more frequent in MM and serve as markers for the transformation of SMM to MM. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
